Anzeige
Mehr »
Mittwoch, 16.07.2025 - Börsentäglich über 12.000 News
Klinisch validiert. Vertriebsbereit. Und kurz vor der FDA-Zulassung.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Marketwired
88 Leser
Artikel bewerten:
(0)

Biometric ID Provider BIO-key Reports Q2 2016 Results

WALL, NJ -- (Marketwired) -- 08/15/16 -- BIO-key International, Inc. (OTCQB: BKYI), an innovative provider of biometric software and hardware solutions for stronger user authentication, today reported results for its second quarter ended June 30, 2016 (Q2'16). BIO-key will host a conference call tomorrow at 10:00 a.m. ET to review its results (details below).

Michael DePasquale, Chairman & CEO of BIO-key, commented, "While we made good incremental progress positioning BIO-key for significant hardware and software revenue opportunities later this year and into next year, our second quarter sales performance was disappointing. Revenue declined to $415,000 in the second quarter as several larger scale opportunities did not close during the period for a variety of reasons that were unrelated to BIO-key. We believe these opportunities still have strong prospects for closing, and we remain in active discussions with the customers to that end. At the same time, we are building out our sales, marketing and distribution channels to drive sales of our line of fingerprint readers for enterprise and retail users.

"We have also continued to build upon our strategic partnership with Microsoft to support the use of expanded biometric security capabilities now resident in the Windows 10 Anniversary Edition released on August 2nd. Windows 10 has already been downloaded on over 350 million devices, providing a substantial and growing market opportunity for our biometric solutions. We believe BIO-key offers the the strongest, most convenient, and cost effective authentication solutions for Windows 10 enterprise and retail users.

"To tackle this opportunity, we are establishing enterprise and retail distribution channels, packaging and collateral, and sales and marketing support and expect to see broad availability of our products in September. In summary, despite the slow start to the year, BIO-key is working a robust pipeline of enterprise hardware and software opportunities. Over the next several months we believe we can convert these opportunities into meaningful revenue growth for the full year 2016, which we now expect to range between $6.0M and $8.5M."

Recent Highlights:

  • Partnered with Access Sales Group to expand distribution and marketing for fingerprint biometric readers and software into high-volume national enterprise and retail channels.
  • BIO-key worked closely with Microsoft's device team to achieve Windows Hello certification of its compact USB fingerprint readers, including web application security extensions to use Windows Hello to sign into Microsoft Edge compatible web sites and apps such as iHeartRadio.
  • Completed development of its enterprise authentication software for Microsoft Active Directory environments. BIO-key's solution ID Director for Windows allows large and small enterprises to leverage BIO-key fingerprint readers for web authentication envirnoments.
  • Expanded sales and production of BIO-key's new SideTouch fingerprint reader. SideTouch combines the new IDEX (IDEX.NO) advanced off-chip sensor technology with BIO-key's universal Windows Biometric Framework (WBF) fingerprint engine. SideTouch is a Microsoft tested and qualified Windows Hello device.
  • Launched availability of SideSwipe and EcoID USB fingerprint readers on Amazon.
  • Expanded sales reach into the Middle East and North Africa via distribution relationship with Moroccan technology provider, Arthur & Co.
  • UK-based former Vodafone & Microsoft executive Pieter Knook was appointed to BIO-key Board.

Guidance:
Managment remains confident in the company's pipeline of hardware and software revenue opportunities for the balance of 2016. However, based on delays in the conversion of several significant opportunities into revenue so far in 2016, BIO-key believes it prudent to reduce its full year revenue guidance to a range of $6.0M - $8.5M in 2016, versus revenue of approximately $5M in 2015. BIO-key's estimated breakeven revenue run rate is approximately $7.5M.

Q2 2016 Results:
Q2'16 total revenue declined to $415,814 compared to $2,272,804 in Q2'15, principally due to a $2.0 million software license from an existing customer in Q2'15. Service revenues, principally comprised of recurring maintenance and support, decreased 13% to $220,926 compared to $255,269 in Q2'15, reflecting an increase in maintenance revenue offset by no special software requirements for current or new customers. License and other revenue decreased to $194,888 from $2,017,535, principally reflecting the $2.0 million software license booked in Q2'15. Hardware sales increased 5% reflecting an increase in volume.

Q2'16 gross margin declined to 67% from 94% in Q2'15, due to lower revenue and a change in revenue mix. Q2'16 operating expenses rose 17% to $1,605,352 compared to $1,373,860 in Q2'15, principally due to increased R&D expense for new personnel, temporary outside services, and recruiting expenses.

BIO-key's Q2'16 net loss to common shareholders was ($1,576,114), or ($0.02) per share, compared to net income of $753,146, or $0.01 per share, in Q2'15.

Liquidity and Capital Resources
At June 30, 2016, BIO-key had cash, cash equivalents and net receivables of $4.3M compared to $7.7M at December 31, 2015.

Conference Call and Webcast Replay

Date/Time: Tuesday, August 16, 2016 at 10 am ET

Dial-In number: 1-877-418-5460 (U.S.), 412-717-9594 (Intl.)

Webcast Replay: http://services.choruscall.com/links/biokey160815 - Available for 30 days.

Call Replay: 1-877-344-7529 U.S. or 412-317-0088 use code 10091361#

About BIO-key International, Inc. (www.bio-key.com)
BIO-key is revolutionizing authentication as our easy to use biometric solutions enable convenient and secure access to information and financial transactions. We eliminate passwords, PINs tokens and cards and make it easy for enterprises and consumers to secure their devices as well as information in the cloud. Our premium finger scanning devices SideSwipe, SideTouch and EcoID offer market leading quality, performance and price.

BIO-key Safe Harbor Statement
Certain statements contained in this press release may be construed as "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of these statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue, our ability to develop new products and evolve existing ones, market acceptance of biometric solutions generally and our specific offerings, our ability to expand into the Asian market, the impact on our business of the recent financial crisis in the global capital markets and negative global economic trends, and our ability to attract and retain key personnel. For a more complete description of these and other risk factors that may affect the future performance of BIO-key International, Inc., see "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015 and its other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made.

Twitter: BIO-keyIR

Investor & Media Contacts:
David Collins, William Jones
Catalyst Global
212-984-9800
bkyi@catalyst-ir.com

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY
                   CONDENSED CONSOLIDATED BALANCE SHEETS

                                                   June 30,    December 31,
                                                     2016          2015
                                                 ------------  ------------
                                                  (Unaudited)
                      ASSETS
Cash and cash equivalents                        $  2,006,665  $  4,321,078
Accounts receivable, net of allowance for
 doubtful accounts of $13,785 at June 30, 2016
 and December 31, 2015                              2,298,744     3,391,405
Due from factor                                         2,323        37,421
Inventory                                             480,039       348,645
Software license rights                             5,000,000     5,000,000
Prepaid expenses and other                             92,855        97,203
                                                 ------------  ------------
  Total current assets                              9,880,626    13,195,752
                                                 ------------  ------------
Software license rights, less current portion       7,000,000     7,000,000
Equipment and leasehold improvements, net              91,083        63,877
Deposits and other assets                               8,712         8,712
Intangible assets--less accumulated amortization      140,935       147,738
                                                 ------------  ------------
  Total non-current assets                          7,240,730     7,220,327
                                                 ------------  ------------
TOTAL ASSETS                                     $ 17,121,356  $ 20,416,079
                                                 ============  ============

                   LIABILITIES
Accounts payable                                 $    696,419  $  1,158,555
Accrued liabilities                                   350,833       493,067
Dividends payable                                     200,625       133,851
Deferred revenue                                      318,046       376,405
Warrant liabilities                                   153,790       104,284
                                                 ------------  ------------
  Total current liabilities                         1,719,713     2,266,162
                                                 ------------  ------------
TOTAL LIABILITIES                                   1,719,713     2,266,162
                                                 ------------  ------------

Commitments and contingencies

               STOCKHOLDERS' EQUITY

Series A-1 convertible preferred stock:
 authorized, 100,000 (liquidation preference of
 $100 per share); issued and outstanding 90,000
 of $.0001 par value                                        9             9
Series B-1 convertible preferred stock;
 authorized, 105,000 (liquidation preference of
$100 per share): issued and outstanding 105,000
 of $.0001 par value                                       11            11
Common stock - authorized, 170,000,000 shares;
 issued and outstanding; 66,339,655 and
 66,098,482 of $.0001 par value at June 30, 2016
 and December 31, 2015, respectively                    6,634         6,610
Additional paid-in capital                         76,545,142    76,754,737
Accumulated deficit                               (61,150,153)  (58,611,450)
                                                 ------------  ------------
TOTAL STOCKHOLDERS' EQUITY                         15,401,643    18,149,917
                                                 ------------  ------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY       $ 17,121,356  $ 20,416,079
                                                 ============  ============


                 BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY
              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                (Unaudited)

                         Three months ended           Six months ended
                              June 30,                    June 30,
                     --------------------------  --------------------------
                         2016          2015          2016          2015
                     ------------  ------------  ------------  ------------
Revenues
  Services           $    220,926  $    255,269  $    505,652  $    505,622
  License fees and
   other                  194,888     2,017,535       340,754     2,416,008
                     ------------  ------------  ------------  ------------
                          415,814     2,272,804       846,406     2,921,630
Costs and other
 expenses
  Cost of services         66,597        56,905       122,379       123,968
  Cost of license
   fees and other          69,893        88,489       125,959       160,782
                     ------------  ------------  ------------  ------------
                          136,490       145,394       248,338       284,750
                     ------------  ------------  ------------  ------------
Gross Profit              279,324     2,127,410       598,068     2,636,880
                     ------------  ------------  ------------  ------------

Operating Expenses
  Selling, general
   and administrative   1,038,904       979,861     2,030,517     2,020,542
  Research,
   development and
   engineering            566,448       393,999     1,055,849       800,640
                     ------------  ------------  ------------  ------------
                        1,605,352     1,373,860     3,086,366     2,821,182
                     ------------  ------------  ------------  ------------
    Operating profit
     (loss)            (1,326,028)      753,550    (2,488,298)     (184,302)
                     ------------  ------------  ------------  ------------
Other income
 (expenses)
  Interest income               7             2            13             4
  Gain (loss) on
   derivative
   liabilities            (49,468)         (406)      (49,506)       14,253
  Income taxes                  -             -          (912)         (912)
                     ------------  ------------  ------------  ------------
  Total other income
   (expenses)             (49,461)         (404)      (50,405)       13,345
                     ------------  ------------  ------------  ------------
Net income (loss)      (1,375,489)      753,146    (2,538,703)     (170,957)
                     ============  ============  ============  ============
Convertible preferred
 stock dividends         (200,625)            -      (401,250)            -
                     ------------  ------------  ------------  ------------
Net income (loss)
 available to common
 stockholders        $ (1,576,114) $    753,146  $ (2,939,953) $   (170,957)
                     ============  ============  ============  ============

Basic and Diluted
 Earnings (Loss) per
 Common Share        $      (0.02) $       0.01  $      (0.04) $      (0.00)
                     ============  ============  ============  ============

Weighted Average
 Shares Outstanding:
  Basic and diluted    66,276,050    66,001,260    66,199,903    66,001,260


                 BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY
               CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (Unaudited)

                                                 Six Months Ended June 30,
                                                 -------------------------
                                                     2016          2015
                                                 -----------   -----------

CASH FLOW FROM OPERATING ACTIVITIES:
  Net loss                                       $(2,538,703)  $  (170,957)
  Adjustments to reconcile net loss to cash used
   in operating activities:
    Depreciation                                      24,577        21,270
    Amortization of intangible assets                  6,803         6,803
    Share-based and warrant compensation for
     employees and consultants                       184,299       222,247
    Loss (gain) on derivative liabilities             49,506       (14,253)
    Stock based directors fees                        39,999             -
  Change in assets and liabilities:
    Accounts receivable trade                      1,092,661       491,356
    Due from factor                                   35,098    (1,465,527)
    Inventory                                       (131,394)     (400,744)
    Prepaid expenses and other                         4,348       162,209
    Accounts payable                                (462,136)      521,803
    Accrued liabilities                             (142,234)      (52,324)
    Deferred revenue                                 (58,359)      172,518
                                                 -----------   -----------
      Net cash used for operating activities      (1,895,535)     (505,599)
                                                 -----------   -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
  Capital expenditures                               (51,783)       (2,078)
                                                 -----------   -----------
      Net cash used for investing activities         (51,783)       (2,078)
                                                 -----------   -----------
CASH FLOW FROM FINANCING ACTIVITIES:
    Preferred dividends paid                        (334,476)            -
    Costs to issue preferred and common stock        (32,619)      (53,579)
                                                 -----------   -----------
      Net cash used for financing activities        (367,095)      (53,579)
                                                 -----------   -----------
NET DECREASE IN CASH AND CASH EQUIVALENTS         (2,314,413)     (561,256)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD     4,321,078       843,632
                                                 -----------   -----------
CASH AND CASH EQUIVALENTS, END OF PERIOD         $ 2,006,665   $   282,376
                                                 ===========   ===========

Investor & Media Contacts:
David Collins, William Jones
Catalyst Global
212-984-9800
bkyi@catalyst-ir.com

© 2016 Marketwired
Hensoldt, Renk & Rheinmetall teuer
Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.